170 related articles for article (PubMed ID: 36563654)
1. Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine.
Desfontaine V; Guinchard S; Marques S; Vocat A; Moulfi F; Versace F; Huser-Pitteloud J; Ivanyuk A; Bardinet C; Makarov V; Ryabova O; André P; Prod'Hom S; Chtioui H; Buclin T; Cole ST; Decosterd L
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Jan; 1215():123555. PubMed ID: 36563654
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma.
Spaggiari D; Desfontaine V; Cruchon S; Guinchard S; Vocat A; Blattes E; Pitteloud J; Ciullini L; Bardinet C; Ivanyuk A; Makarov V; Ryabova O; Buclin T; Cole ST; Decosterd LA
PLoS One; 2019; 14(5):e0217139. PubMed ID: 31150423
[TBL] [Abstract][Full Text] [Related]
3. [The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone (PBTZ169)].
Mariandyshev AO; Khokhlov AL; Smerdin SV; Shcherbakova VS; Igumnova OV; Ozerova IV; Bolgarina AA; Nikitina NA
Ter Arkh; 2020 Apr; 92(3):61-72. PubMed ID: 32598795
[TBL] [Abstract][Full Text] [Related]
4. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
Mercier T; Desfontaine V; Cruchon S; Da Silva Pereira Clara JA; Briki M; Mazza-Stalder J; Kajkus A; Burger R; Suttels V; Buclin T; Opota O; Koehler N; Sanchez Carballo PM; Lange C; André P; Decosterd LA; Choong E
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123456. PubMed ID: 36240540
[TBL] [Abstract][Full Text] [Related]
5. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous determination of a novel oxazolidinone anti-tuberculosis OTB-658 and its metabolites in monkey blood by LC-MS/MS.
Jiang J; Liu Y; Liu X; Zhang D; Huang H; Wang B; Sheng L; Li Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Mar; 1167():122552. PubMed ID: 33588346
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of High-Throughput Bioanalytical Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Quantification of Newly Synthesized Antitumor Carbonic Anhydrase Inhibitors in Human Plasma.
Abdel-Megied AM; Eldehna WM; Abdelrahman MA; Elbarbry FA
Molecules; 2020 Dec; 25(23):. PubMed ID: 33291270
[TBL] [Abstract][Full Text] [Related]
8. Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography-tandem mass spectrometry.
He G; Guo B; Zhang J; Li Y; Wu X; Fan Y; Chen Y; Cao G; Yu J
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1081-1082():87-100. PubMed ID: 29518721
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development.
Magotra A; Sharma A; Gupta AP; Wazir P; Sharma S; Singh PP; Tikoo MK; Vishwakarma RA; Singh G; Nandi U
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():200-206. PubMed ID: 28623772
[TBL] [Abstract][Full Text] [Related]
10. Characterization of degradation products of Macozinone by LC-MS/MS and elucidation of their degradation pathway.
Guo K; Shan Y; Zhang T; Li G; Li P; Ma C
J Pharm Biomed Anal; 2022 Sep; 219():114865. PubMed ID: 35716420
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.
Kivrane A; Grinberga S; Sevostjanovs E; Igumnova V; Pole I; Viksna A; Bandere D; Krams A; Cirule A; Pugovics O; Ranka R
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122986. PubMed ID: 34688197
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of NTB-3119, a novel anti-tuberculosis agent, and its major metabolites in mouse plasma by LC-MS/MS and its application in preclinical pharmacokinetics study.
Wang X; Lang X; Wang F; Tan H; Li G; Li P; Hu J; Wang B; Li Y
J Pharm Biomed Anal; 2023 Feb; 224():115172. PubMed ID: 36435083
[TBL] [Abstract][Full Text] [Related]
13. Comparison of conventional liquid chromatography-tandem mass spectrometry versus microflow liquid chromatography-tandem mass spectrometry within the framework of full method validation for simultaneous quantification of 40 antidepressants and neuroleptics in whole blood.
Steuer AE; Poetzsch M; Koenig M; Tingelhoff E; Staeheli SN; Roemmelt AT; Kraemer T
J Chromatogr A; 2015 Feb; 1381():87-100. PubMed ID: 25596763
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Dearomatization of the Potent Antituberculosis Agent BTZ043 via Meisenheimer Complex Formation.
Kloss F; Krchnak V; Krchnakova A; Schieferdecker S; Dreisbach J; Krone V; Möllmann U; Hoelscher M; Miller MJ
Angew Chem Int Ed Engl; 2017 Feb; 56(8):2187-2191. PubMed ID: 28097740
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples.
Reckers A; Huo S; Esmail A; Dheda K; Bacchetti P; Gandhi M; Metcalfe J; Gerona R
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Apr; 1169():122467. PubMed ID: 33713954
[TBL] [Abstract][Full Text] [Related]
16. Simple, fast and sensitive LC-MS/MS analysis for the simultaneous quantification of nicotine and 10 of its major metabolites.
Piller M; Gilch G; Scherer G; Scherer M
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Mar; 951-952():7-15. PubMed ID: 24508673
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of an LC-MS/MS method for determination of a novel anticancer agent (CPI-613) in human plasma.
Reddy NR; Reddy V; Boteju A; Boteju L; Voelker T; Liu S; Hu K
Bioanalysis; 2022 Mar; 14(5):253-266. PubMed ID: 35172610
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.
Roosendaal J; Wang K; Rosing H; Lucas L; Gebretensae A; Oganesian A; Schellens JHM; Beijnen JH; Lin ZJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Mar; 1109():132-141. PubMed ID: 30754019
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a high-throughput micro solid-phase extraction method coupled with ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry for rapid identification and quantification of phenolic metabolites in human plasma and urine.
Feliciano RP; Mecha E; Bronze MR; Rodriguez-Mateos A
J Chromatogr A; 2016 Sep; 1464():21-31. PubMed ID: 27527878
[TBL] [Abstract][Full Text] [Related]
20. A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma.
Iacuzzi V; Zanchetta M; Gagno S; Poetto AS; Orleni M; Marangon E; Guardascione M; Foltran L; Posocco B; Toffoli G
J Pharm Biomed Anal; 2020 Aug; 187():113358. PubMed ID: 32460216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
